Annals of Nuclear Medicine

, Volume 18, Issue 5, pp 363–368 | Cite as

Antisense targeting in cell culture with radiolabeled DNAs —a brief review of recent progress—



The promise of antisense targeting that any tissue with a unique genetic expression can be specifically localized with radioactivity in the living subject is the holy grail that drives this research today. If antisense targeting were to achieve even a fraction of its promise, the results could well lead a revolution in diagnostic nuclear medicine. Despite its obvious complexities, antisense targeting with radiolabeled oligomers such as DNA is making considerable progress in cell culture. As is documented in this brief review, evidence is becoming overwhelming that an antisense mechanism is probably responsible for the accumulation in tumor cells in culture of radiolabeled DNAs with base sequences antisense to target messenger RNAs (mRNAs). That an increased accumulations of these DNAs compared to control DNAs has now been seen in a substantial number of tumor cell types and mRNA targets largely eliminates any possibility of an aptameric effect being responsible for these specific accumulations. In addition, the number of antisense DNAs accumulating specifically in cells in culture has been shown to be orders of magnitude larger than that expected on the basis of steady state mRNA levels. Thus, two of the main concerns regarding antisense targeted, namely that the mechanism of localization may not be attributed to antisense and that the degree of accumulation will be impractically low for imaging, have been addressed in recent research. The remaining obstacle to successful targeting may be delivery. This review will provide a brief review of recent results, primarily from the laboratory of one of the authors (DJH), obtained in tissue culture in studies of antisense targeting and will conclude with several suggestions for future approaches.

Key words

antisense cells technetium-99m 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hnatowich DJ. Antisense and Nuclear Medicine.J Nucl Med 1999; 40:693–7033.PubMedGoogle Scholar
  2. 2.
    Hnatowich DJ. Antisense and Nuclear Medicine. Where are we now?Cancer Biotherapy and Radiopharmaceuticals 2000; 15:447–4577.Google Scholar
  3. 3.
    Crook ST. Basic principles of antisense technology. Ed. Crook ST.In Antisense Drug Technology. Principles, Strategies, and Applications. New York; Marcel Dekker, Inc., 2001: 14.Google Scholar
  4. 4.
    Henry CM. High hopes for RNA Interference.Chem Engineering News 2003; 22 December.Google Scholar
  5. 5.
    Glaser V. Antisense drugs hope to enter the mainstream.Genetic Engineering News 2003; 15 October.Google Scholar
  6. 6.
    Urbain JLC, Shore SK, Vekemans MC, Cosenza SC, DeRiel K, Parel GV, et al. Scintigraphic imaging of oncogenes with antisense probes: does it make sense?Eur J Nucl Med 1995; 22:499–5044.PubMedGoogle Scholar
  7. 7.
    Zhang YM, Liu N, Zhu ZH, Rusckowski M, Hnatowich DJ. Influences of three chelators (HYNIC, MAG3 and DTPA) on thein vitro andin vivo behaviors of99mTc attached to antisense DNA.Eur J Nucl Med 2000; 27:1700–17077.PubMedCrossRefGoogle Scholar
  8. 8.
    Tortora G, Caputo R, Damiano V, Bianco R, Pep S, Bianco AR, et al. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A.Proc Natl Acad Sci USA 1997;94:12586–125911.CrossRefGoogle Scholar
  9. 9.
    Qu T, Wang Y, Zhu Z, Rusckowski M, Hnatowich DJ. Different chelators and different peptides together influence thein vitro and mousein vivo properties of99mTc.Nucl Med Comm 2001; 22:203–2155.CrossRefGoogle Scholar
  10. 10.
    Zhang YM, Wang Y, Liu N, Zhu ZH, Rusckowski M, Hnatowich DJ.In vitro investigations of tumor targeting with99mTc-labeled antisense DNA.J Nucl Med 2001; 42:1660–1669.PubMedGoogle Scholar
  11. 11.
    Zhang Y, Rusckowski M, Liu N, Liu C, Hnatowich DJ. Cationic liposomes enhance cellular/nuclear localization of99mTc-antisense oligonucleotides in target tumor cells.Cancer Biotherapy and Radiopharmaceuticals 2001; 16:411–419.PubMedCrossRefGoogle Scholar
  12. 12.
    Nakamura K, Liu G, Zhang Y, Kubo A, Hnatowich DJ. Antisense targeting of P-glycoprotein MDR expression in tissue culture, [abstract]J Nucl Med 2003; 44(Suppl):p304.Google Scholar
  13. 13.
    Hjelstuen OK, Maelandsom GM, Tonnesen HH, Bremmer PO, Verbruggen AM. Uptake of99mTc- and32P-labeled oligodeoxynucleotides in osteosarcoma (OHS) cell lines.J Lab Comp Radiopharm 1999; 42:1215–12277.CrossRefGoogle Scholar
  14. 14.
    Stalteri MA, Mather DJ. Hybridization and cell uptake studies with radiolabelled antisense oligonucleotides.Nucl Med Comm 2001; 22:1171–11799.CrossRefGoogle Scholar
  15. 15.
    Lewis MR, Jia F. Antisense imaging: and miles to go before we sleep?J Cell Biochem 2003; 90:464–4744.PubMedCrossRefGoogle Scholar
  16. 16.
    Younes CK, Boisgard R, Tavitian B. Labeled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives.Current Pharm Design 2002; 8:1451–14666.CrossRefGoogle Scholar
  17. 17.
    Wang J, Chen P, Mrkobrada M, Hu M, Vallis KA, Reilly RM. Antisense imaging of epidermal growth factor-inducedp21WAF-1/CIP-1 gene expression in MDA-MB-468 human breast cancer xenografts.Eur J Nucl Med 2003; 30:1273–12800.CrossRefGoogle Scholar
  18. 18.
    Lewis MR, Jia F, Gallazzi F, Wang T, Zhang J, Shenoy N, et al. Radiometal-labeled peptide-PNA conjugates for targeting bcl-2 expression: preparation, characterization, andin vitro mRNA binding.Bioconj Chem 2002; 13:1176- 11800.CrossRefGoogle Scholar
  19. 19.
    Sato N, Kobayashi H, Saga T, Nakamoto Y, Ishimori T, Togashi K, et al. Tumor targeting and imaging of intraperi- toneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice.Clin Cancer Res 2001; 7:3600–36011.Google Scholar
  20. 20.
    Wang L, Prakash RH, Steine CA, Koehn RK, Ruffner DE. Progress in the delivery of therapeutic oligonucleotides: Organ/cellular distribution and targeted delivery of oligonucleotidesin vivo. Antisense Nucleic Acid Drug Dev 2003 ; 13:169–1899.PubMedCrossRefGoogle Scholar
  21. 21.
    Dewanjee MK, Ghafouripour AK, Kapodvanjwala M, Dewanjee S, Sarafini AN, Lopez DM, et al. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model.J Nucl Med 1994; 35: 1054–1063.PubMedGoogle Scholar
  22. 22.
    Zhang Y, Liu C, Liu N, Ferro Flores G, Rusckowski M, Hnatowich DJ. Electrostatic Binding with Tat and other Cationic Peptides Increases Cell Accumulation of99mTc- Antisense DNAs without Entrapment.Mol Imaging Biol 2003; 5: 240–247.PubMedCrossRefGoogle Scholar
  23. 23.
    Zhang Y, Liu C, Zhang S, He J, Rusckowski M, Hnatowich DJ. Improved antisense vs. control accumulations in cells using99mTc labeled morpholinos as alternatives to labeled DNAs when incubated naked, [abstract]J Nucl Med 2002; 43 (Suppl): 138.Google Scholar

Copyright information

© Springer 2004

Authors and Affiliations

  1. 1.Division of Nuclear Medicine, Department of RadiologyUniversity of Massachusetts Medical SchoolWorcesterUSA
  2. 2.Department of RadiologyKeio University School of MedicineTokyoJapan

Personalised recommendations